Literature DB >> 20551476

Establishing efficacy of human products using animals: the US food and drug administration's "animal rule".

P J Snoy1.   

Abstract

In 2002, the US Food and Drug Administration issued regulations to allow the approval of human drugs and biological products based on animal efficacy studies when human efficacy studies would be unethical or not feasible. These regulations are intended to assist in the approval process for products aimed at preventing or treating human diseases caused by nuclear, radiological, biological, and chemical agents that have the potential to harm a significant percentage of the US population. This article discusses the criteria that must be met to use the Animal Rule to demonstrate efficacy in place of human clinical trials.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20551476     DOI: 10.1177/0300985810372506

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  47 in total

1.  Radionuclide decorporation: matching the biokinetics of actinides by transdermal delivery of pro-chelators.

Authors:  Yong Zhang; Matthew P Sadgrove; Russell J Mumper; Michael Jay
Journal:  AAPS J       Date:  2013-08-30       Impact factor: 4.009

Review 2.  Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate.

Authors:  Tetsuro Ikegami
Journal:  Expert Rev Vaccines       Date:  2017-05-02       Impact factor: 5.217

Review 3.  Are there relevant animal models to set research priorities in LUTD? ICI-RS 2019.

Authors:  Karl-Erik Andersson; Lori Birder; Christopher Chermansky; Russell Chess-Williams; Christopher Fry
Journal:  Neurourol Urodyn       Date:  2020-07       Impact factor: 2.696

4.  The attenuated NYCBH vaccinia virus deleted for the immune evasion gene, E3L, completely protects mice against heterologous challenge with ectromelia virus.

Authors:  Karen L Denzler; Jill Schriewer; Scott Parker; Chas Werner; Hollyce Hartzler; Ed Hembrador; Trung Huynh; Susan Holechek; R M Buller; Bertram L Jacobs
Journal:  Vaccine       Date:  2011-10-05       Impact factor: 3.641

Review 5.  What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans? The Importance of Bridging Studies and Species-Independent Correlates of Protection.

Authors:  Hana Golding; Surender Khurana; Marina Zaitseva
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

6.  Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA.

Authors:  Emily P Thi; Chad E Mire; Raul Ursic-Bedoya; Joan B Geisbert; Amy C H Lee; Krystle N Agans; Marjorie Robbins; Daniel J Deer; Karla A Fenton; Ian MacLachlan; Thomas W Geisbert
Journal:  Sci Transl Med       Date:  2014-08-20       Impact factor: 17.956

7.  Development of a novel nonhuman primate model for Rift Valley fever.

Authors:  Darci R Smith; Brian H Bird; Bridget Lewis; Sara C Johnston; Sarah McCarthy; Ashley Keeney; Miriam Botto; Ginger Donnelly; Joshua Shamblin; César G Albariño; Stuart T Nichol; Lisa E Hensley
Journal:  J Virol       Date:  2011-12-07       Impact factor: 5.103

Review 8.  Improving the predictive value of interventional animal models data.

Authors:  Caroline J Zeiss
Journal:  Drug Discov Today       Date:  2014-11-04       Impact factor: 7.851

Review 9.  The search for animal models for Lassa fever vaccine development.

Authors:  Igor S Lukashevich
Journal:  Expert Rev Vaccines       Date:  2013-01       Impact factor: 5.217

Review 10.  Post-exposure treatments for Ebola and Marburg virus infections.

Authors:  Robert W Cross; Chad E Mire; Heinz Feldmann; Thomas W Geisbert
Journal:  Nat Rev Drug Discov       Date:  2018-01-29       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.